These and other trends are presented in Pharmaceutical Packaging Market in the US, 12th Edition, a new study from The Freedonia Group, a Cleveland-based industry research firm.
In OTC drug packaging applications, growth prospects for blister packaging will benefit from recent and forthcoming switches of previously prescription-only drugs to nonprescription distribution. For example, Xyzal, a leading allergy treatment, received FDA approval for OTC sale in January 2017. The OTC version of this medication is sold in a 35-tablet compartment blister pack.
The following factors will spur growth for pharmaceutical blister packaging:
- Ongoing improvements in materials and design capabilities
- Advantages related to patient drug adherence, prevention of institutional drug distribution errors, barrier protection, child resistance, and security
- Advances in processing and filling equipment
- Accelerating growth in oral medication demand spurred by the introduction of new chronic care medicines and the expansion of prescription drug coverage
Pharmaceutical blister packaging demand by format in 2016 was 61.6% compartment, 29.1% slide, and 9.3% wallet.